Cell4Pharma

Vesicular Transport Assays for Drug-Drug Interaction and Substrate Studies

Cell4Pharma provides Vesicular Transport Assays to support drug-drug interaction and substrate studies. These assays utilize human drug efflux transporters (ABC transporters), which are transiently overexpressed in human embryonic kidney (HEK293) cells. Inside-out membrane vesicles derived from these cells enable high-throughput applications, ensuring reproducible and reliable results.

Key Features:

• ATP-Dependent Transport: Transporters actively translocate substrates into membrane vesicles.
• Multiple Detection Methods: Substrates can be detected using radiolabeling, fluorescence, or LC-MS.
• High-Quality Production: Large, uniform batches with guaranteed transport ratios are provided.

Vesicle Kit Contents (for 100 Reactions):

• Membrane vesicles
• AMP solution
• ATP solution
• Assay buffer
• Stop/Wash buffer

Novel Fluorescent Substrate: FluoPgp

Cell4Pharma offers FluoPgp, an innovative fluorescent substrate designed for improved sensitivity and assay performance.

For reliable vesicular transport solutions, Cell4Pharma delivers high-quality assay components tailored for pharmaceutical and biomedical research.

Superior Dynamic Range in Vesicular Transport Assays

Cell4Pharma’s vesicles offer an unmatched dynamic range compared to other solutions on the market, ensuring higher sensitivity and reliability for drug transport studies. Their high-quality vesicles are available for a range of key efflux transporters, including:

• P-glycoprotein (PgP)
• Bile Salt Export Pump (BSEP)
• Multidrug Resistance Proteins (MRP1, MRP2, MRP3, MRP4, MRP5, MRP8)
• Breast Cancer Resistance Protein (BCRP)

With Cell4Pharma’s vesicular transport solutions, researchers can achieve superior performance in drug-drug interaction and substrate studies.

ciPTEC – Human renal cell line mimicking proximal tubule cells of the kidney

Cell4Pharma’s mission is to reduce the number of drug failures due to renal toxicity during the clinical phase of drug development.

They envision a world without the risk of renal toxicity for compounds entering the clinical phase of drug development. Cell4Pharma aims to reduce the rate of late-stage clinical failures due to renal toxicity to below 3% market-wide within the next 10 years. Without the use of animal testing. This ambition is supported by their human renal cell lines; ciPTEC, validated through extensive collaborations with the pharmaceutical industry. More than 10 years of research have led to the development of robust cell-based assays focused on the detection of highly specific biomarkers of renal toxicity. ciPTEC consists of three cell lines.

• • ciPTEC endogenously expresses the most relevant renal drug transporters.

• • ciPTEC is an excellent tool for predicting pharmacokinetics, drug-drug interactions and renal toxicity of potential pharmaceutical compounds.

• • ciPTEC is a highly stable human cell line with preserved tubular characteristics and transporter functionality.

A selection of successful ciPTEC assay applications

• • Cell viability: MTT, WST8, cell count

• • Transporter activity: Pgp, BCRP, MRPs, OCT2, OAT1, OAT3

• • Receptor-mediated endocytosis: Megalin/Cubilin

• • Metabolic enzyme function and expression: CYP, UGT, GST Cytokine production, 3D microfluidic cultures, cilia expression, gene expression analysis, LDH and NAG release, secretion of miRNAs, ATP production, lactate production, O2 consumption, genetic modification using CRISPR/Cas, Baculo virus, Lenti virus, and Retro virus, and ROS production.

Product lines from Cell4Pharma

• • ciPTEC 14.4 primary cells

• • ciPTEC OAT 1

• • ciPTEC OAT 3

Bio-Connect supplies all their products in the Benelux. If you have any questions, please contact the helpdesk.